Literature DB >> 25896908

Urinary Trypsin Inhibitor Reduced Inflammation Response Induced by Hyperlipidemia.

Ying Deng1, Junying Kong2.   

Abstract

INTRODUCTION AND
OBJECTIVES: Atherosclerosis is recognized as a chronic inflammatory disease. The aim of this study was to examine the role of urinary trypsin inhibitor (UTI) in inflammation response induced by hyperlipidemia in rabbits.
METHODS: Thirty rabbits after injury of the right iliac artery endothelium were randomly divided into 3 groups: control group, model group, and UTI group. Iliac arteries were isolated and histology was performed on arterial regions that were injured by balloon after 8 weeks. Neointimal thickness (NT) and neointimal to media radio (N/M) were measured. Blood lipids, interleukin 6, and tumor necrosis factor-α were evaluated. Macrophages were evaluated by immunohistochemical analysis. MicroRNA-181b (miR-181b) was measured by reverse transcriptase-polymerase chain reaction.
RESULTS: Urinary trypsin inhibitor therapy decreased serum inflammatory factor levels without significant changes in blood lipids. Compared with model group, UTI reduced macrophage infiltration of iliac artery (13.91 ± 2.03% vs 24.21 ± 8.94%, P < .01). Hyperlipidemia reduced the expression of miR-181b and increased NT and N/M ratio. Systemic administration of UTI rescued miR-181b expression and inhibited neointimal formation.
CONCLUSIONS: Urinary trypsin inhibitor could reduce neointimal hyperplasia by inhibiting inflammatory response induced by hyperlipidemia and may become a potential antiatherosclerosis supplement.
© The Author(s) 2015.

Entities:  

Keywords:  atherosclerosis; hyperlipidemia; inflammation

Mesh:

Substances:

Year:  2015        PMID: 25896908     DOI: 10.1177/1074248415578907

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  4 in total

1.  Relationship between XspI Site Polymorphisms of LDL-R Gene and Serum IL-2 and IL-10 in Patients with Hypercholesterolemia.

Authors:  Mingming Zhang; Yamin Lu; Xin Liu; Xiaobin Zhang; Cuigai Zhang; Wei Gao; Yanqing Tie
Journal:  J Clin Lab Anal       Date:  2016-04-28       Impact factor: 2.352

2.  Blockade of NF-κB and MAPK pathways by ulinastatin attenuates wear particle-stimulated osteoclast differentiation in vitro and in vivo.

Authors:  Jiang-Ying Ru; Hai-Dong Xu; Dai Shi; Jun-Bo Pan; Xiao-Jin Pan; Yan-Fen Wang
Journal:  Biosci Rep       Date:  2016-10-27       Impact factor: 3.840

3.  Transcriptome analysis of arterial and venous circulating miRNAs during hypertension.

Authors:  Ling Jin; Min Li; Hao Wang; Zhongnan Yin; Li Chen; Yang Zhou; Yongzheng Han; Qinghua Cui; Yuan Zhou; Lixiang Xue
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.379

4.  Ulinastatin Inhibits the Proliferation, Invasion and Phenotypic Switching of PDGF-BB-Induced VSMCs via Akt/eNOS/NO/cGMP Signaling Pathway.

Authors:  Cheng Huang; Weihui Huang; Rui Wang; Yongli He
Journal:  Drug Des Devel Ther       Date:  2020-12-14       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.